📰 Advicenne News
Page 3 - Advicenne News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Advicenne. Real-time updates on events, politics, business and more.
March 31, 2022
Significant regulatory and commercial progress for SibnayalTM Control of expenses with a net loss reduced to €12.4 million (vs. €14.8 million) Closing cash position at €12.7 million.
March 31, 2022
Significant regulatory and commercial progress for SibnayalTM Control of expenses with a net loss reduced to €12.4 million (vs. €14.8 million) Closing cash position at €12.7 million.
March 30, 2022
Regulatory News: Advicenne (Euronext: ALDVI) (Paris:ALDVI), a pharmaceutical company specializing in the development and commercialization of innovative treatments for those suffering from rare renal
January 21, 2022
Regulatory News: The ordinary shareholders' meeting of Advicenne (Paris:ADVIC) (FR0013296746 ADVIC the "Company") held today, approved the proposed transfer of the listing of the Company's shares
January 18, 2022
18.01.2022 - Regulatory News: Advicenne (Euronext: ADVIC) (Paris:ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, announces today sales of €3.3 million in ...
January 18, 2022
Regulatory News: Advicenne (Euronext: ADVIC) (Paris:ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal
January 4, 2022
Advicenne will receive a transfer price and royalties for an amount markedly higher than 50% of future sales of Sibnayal - Sibnayal will be marketed to one-third of European patients by three members
December 27, 2021
Regulatory News: Advicenne (Euronext: ADVIC) (Paris:ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal
December 20, 2021
20.12.2021 - Regulatory News: Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, announces is has received a positive opinion from the ... Seite 1
December 3, 2021
Regulatory News: At its meeting today, the Board of Directors of Advicenne (FR0013296746 ADVIC the "Company") (Paris:ADVIC) (BSE:ADVIC) decided to submit to the ordinary general meeting of shareholders